Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

What Is Embolism? What Are The Different Types Of Embolism?
An embolism - from the Greek çİmbolos meaning "stopper" or "plug" - is the term that describes a condition where an object called an embolus is created in one part of the body, circulates throughout the body, and then blocks blood flowing through a vessel in another part of the body. Emboli (plural of embolus) are not to be confused with thrombi (plural of thrombus), which are clots that are formed and remain in one area of the body without being carried throughout the bloodstream.
generic viagra online
Three New Quality Re Guides Added To MetLife's Dental Continuing Education Program
MetLife, providing dental plan administration for over 21 million people, announced additions to its dental continuing education program today. Three new quality re guides have been added to the MetLife program, which is recognized by the American Dental Association (ADA) and the Academy of General Dentistry (AGD). The new courses focus on: 1) Assessing Orofacial Pain, 2) Assessing Risk for Chronic Periodontitis in Adults 3rd Edition, and 3) Recognition and Management of Patients with Xerostomia 2nd Edition. The courses are available online at http://www.metdental.com and can be completed for continuing education credits.
News of the day
Arizona ADAP Cuts Number Of Medications Covered Under Program
The Arizona AIDS Drug Assistance Program (ADAP) has reduced the number of medications it will cover - antiretrovirals and drugs that treat opportunistic infections will not be affected, the Arizona Daily Star reports. The program relies heavily on federal funding. Judy Norton, chief of the state"s Office of HIV, STD and Hepatitis C Services, said the state received $2.3 million less than what it requested from the federal government, requiring the program to make cuts. According to the Daily Star, federal ADAP funds are "drying up as drug costs rise and as more" people living with HIV/AIDS are enrolling in the program. The Arizona ADAP has been serving about 1,100 patients statewide, although the number has gone up in recent months, Laura Oxley, Arizona Department of Health Services spokesperson, said. A letter explaining the changes to the program was sent to clients and providers earlier this week (Innes, Arizona Daily Star, 6/11).
Mental Health

PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound

PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by PharmaMar"s internal research program. The first patient enrolled in the trial has already started treatment with the compound. PM1183 is a new synthetic alkaloid which binds to the minor groove of DNA, generates DNA double strand breaks and caused cell cycle perturbation that finally results in a specific type of cell death calles apoptosis. Results from preclinical studies indicate a pattern of activity of PM1183 different from that of conventional alkylating agents. In preclinical studies PM1183 demonstrated strong in vitro and in vivo antitumoural activity in a wide variety of tumour cell lines and human transplantable xenografted tumours. PM11883 also demonstrated a manageable and reversible preclinical toxicology profile. As a single agent, PM1183 significantly reduced tumor proliferation in vivo, with the strongest effect observed on the xenografts of the breast cancer cell line MX1. PM1183 was also evaluated for in vivo activity using M5076 sarcoma model that spontaneously metastasizes in the liver of the C57Bl/6 female tumor bearing mice. The compound statistically reduced the number of liver metastasis compared to placebo-treated animal. In vitro studies show cell lines with mutant p53 or lacking P53 are more sensitive with PM1183. Further studies are on going in human ovarian cancer and human sarcoma xenografts. PharmaMar"s clinical portfolio currently includes five new, first-in-class compounds: Yondelis®, Aplidin®, Zalypsis®, Irvalec® and PM1183. The PharmaMar patent portfolio is composed of over 1,800 files and it has a continous flow of new compound into the clinic (1 new compound every 24 months). About PM1183 PM1183 is a new synthetic alkaloid compound developed by PharmaMar"s internal research program. It binds to the minor groove of DNA, generates DNA double strand brakes and caused cell cycle perturpation mainly consisting in a delayed progression of S phase and cycle arrest in G2M. Results from preclinical studies indicate a pattern of activity of PM1183 different from that of conventionaol alkylating agents. PharmaMar PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar"s first product, Yondelis®, received marketing authorisation from the European Commission for the treatment of advanced or metastatic soft tissue sarcoma in September 2007. In 2008 a registration dossier was submitted to the European Medicines Agency (EMEA) and Food and Drug Administration (FDA, USA) for Yondelis® when administered in combination with DOXIL®/Caelyx™ (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer. It is also in phase II clinical trials for prostate, breast, and lung cancers. Three other PharmaMar compounds, Aplidin®, Irvalec®, and Zalypsis® are in various stages of clinical development. PharmaMar


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009